AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Assessment of planning target volume margins in 1.5 T magnetic resonance-guided stereotactic body radiation therapy for localized prostate cancer

Bin Yang1 ( )Jing Yuan2Darren M.C. Poon3Hui Geng1Wai Wang Lam1Kin Yin Cheung1Siu Ki Yu1
Medical Physics Department, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China
Research Department, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China
Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China
Show Author Information

Abstract

Objective

We aimed to determine the planning target volume margins applicable to magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) of localized prostate cancer on a 1.5 T MR-Linac.

Methods

A total of 10 patients with low- to intermediate-risk prostate cancer were retrospectively enrolled. All patients received five-fraction MRgSBRT treatments, and underwent daily endorectal ballooning and bladder control. Five patients were implanted with the hydrogel rectal spacer. Three MR scans at each fraction were acquired to evaluate the intrafractional prostate motion. The required planning target volume margin was determined using the van Herk margin recipe based on direct MR-MR prostate registration. The set-up margin for localization using bony anatomy was also estimated.

Results

The mean and standard deviation of translational displacement in left-right (LR), superior-inferior (SI), and anterior-posterior (AP) directions were –0.3 ± 0.7, 2.0 ± 1.5, and 1.4 ± 1.1 mm, respectively. Planning target volume margins over the MRgSBRT fraction duration were 2.8 (LR), 5.3 (SI), and 3.9 mm (AP). Set-up margins were estimated to 2.6 (LR), 3.3 (SI), and 3.3 mm (AP). Prostate motion increased considerably with treatment duration. Adapt-to-position had smaller intrafractional motions than adapt-to-shape. The rectal spacer insignificantly (p > 0.1) reduced the prostate motion in SI and AP.

Conclusion

Online workflow efficiency enhancement and intrafractional motion monitoring are vital for planning target volume margin reduction and precision enhancement in MRgSBRT.

References

1

Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019; 20(11): 1531-1543.

2

Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019; 104(4): 778-789.

3

Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196): 385-395.

4

de Crevoisier R, Tucker SL, Dong L, et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 62(4): 965-973.

5

Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 84(1): 125-129.

6

Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8(6): 475-487.

7

Crehange G, Mirjolet C, Gauthier M, et al. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiother Oncol. 2012; 103(2): 244-246.

8

Henke LE, Contreras JA, Green OL, et al. Magnetic resonance image-guided radiotherapy (MRIgRT): a 4.5-year clinical experience. Clin Oncol (R Coll Radiol). 2018; 30(11): 720-727.

9

Kupelian P, Sonke JJ. Magnetic resonance-guided adaptive radiotherapy: a solution to the future. Semin Radiat Oncol. 2014; 24(3): 227-232.

10

Lagendijk JJ, Raaymakers BW, Van den Berg CA, Moerland MA, Philippens ME, van Vulpen M. MR guidance in radiotherapy. Phys Med Biol. 2014; 59(21): R349-R369.

11

Mohajer J, Dunlop A, Mitchell A, et al. Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer. Clin Transl Radiat Oncol. 2020; 26: 1-7.

12

Poon DMC, Yuan J, Wong OL, et al. 1.5T Magnetic resonance-guided stereotactic body radiotherapy for localized prostate cancer: preliminary clinical results of clinician- and patient-reported outcomes. Cancers (Basel). 2021; 13(19): 4866.

13

Winkel D, Bol GH, Kroon PS, et al. Adaptive radiotherapy: the Elekta Unity MR-linac concept. Clin Transl Radiat Oncol. 2019; 18: 54-59.

14

Yuan J, Poon DMC, Lo G, Wong OL, Cheung KY, Yu SK. A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer. Quant Imaging Med Surg. 2022; 12(2): 1585-1607.

15

Levin-Epstein R, Qiao-Guan G, Juarez JE, et al. Clinical assessment of prostate displacement and planning target volume margins for stereotactic body radiotherapy of prostate cancer. Front Oncol. 2020; 10:539. https://doi.org/10.3389/fonc.2020.00539

16

Yartsev S, Bauman G. Target margins in radiotherapy of prostate cancer. Br J Radiol. 2016; 89(1067):20160312. https://doi.org/10.1259/bjr.20160312

17

Xue C, Yuan J, Poon DM, et al. Reliability of MRI radiomics features in MR-guided radiotherapy for prostate cancer: repeatability, reproducibility, and within-subject agreement. Med Phys. 2021; 48(11): 6976-6986.

18

van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47(4): 1121-1135.

19

van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004; 14(1): 52-64.

20

Agergaard S, Jensen H. R. & Brink C. Is daily IGRT needed for prostate patients? Radiother Oncol, 2011; 99:1. https://doi.org/10.1016/S0167-8140(11)71395-0

21

Magli A, Urpis M, Crespi M, et al. Assessment of PTV margins accounting for prostate intrafraction motion in SBRT with online IGRT. Clin Oncol (R Coll Radiol). 2017; 2; 1275.

22

Hinton BK, Fiveash JB, Wu X, Dobelbower MC, Kim RY, Jacob R. Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients. ISRN Oncol. 2013; 2013:941269. https://doi.org/10.1155/2013/941269

23

Curtis W, Khan M, Magnelli A, Stephans K, Tendulkar R, Xia P. Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data. Int J Radiat Oncol Biol Phys. 2013; 85(3): 700-706.

24

Tree A, Jones C, Sohaib A, Khoo V, van As N. Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method? Radiat Oncol. 2013; 8:228. https://doi.org/10.1186/1748-717X-8-228

25

Alongi F, Rigo M, Figlia V, et al. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol. 2020; 15(1): 69.

26

Gladwish A, Pang G, Cheung P, D'Alimonte L, Deabreu A, Loblaw A. Prostatic displacement during extreme hypofractionated radiotherapy using volumetric modulated arc therapy (VMAT). Radiat Oncol. 2014; 9:262. https://doi.org/10.1186/s13014-014-0262-y

27

Mazzola R, Figlia V, Rigo M, et al. Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. J Cancer Res Clin Oncol. 2020; 146(9): 2379-2397.

28

Kotte AN, Hofman P, Lagendijk JJ, van Vulpen M, van der Heide UA. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2007; 69(2): 419-425.

29

Christiansen RL, Dysager L, Hansen CR, et al. Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment. Radiother Oncol. 2022; 167: 165-171.

30

Badakhshi H, Wust P, Budach V, Graf R. Image-guided radiotherapy with implanted markers and kilovoltage imaging and 6-dimensional position corrections for intrafractional motion of the prostate. Anticancer Res. 2013; 33(9): 4117-4121.

31

Beltran C, Herman MG, Davis BJ. Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods. Int J Radiat Oncol Biol Phys. 2008; 70(1): 289-295.

32

Corradini S, Alongi F, Andratschke N, et al. MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol. 2019; 14(1): 92.

33

Afkhami Ardekani M, Ghaffari H. Optimization of prostate brachytherapy techniques with polyethylene glycol-based hydrogel spacers: a systematic review. Brachytherapy. 2020; 19(1): 13-23.

34

Hwang ME, Mayeda M, Liz M, et al. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes. Radiat Oncol. 2019; 14(1): 136.

35

Cuccia F, Mazzola R, Nicosia L, et al. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiat Oncol. 2020; 15(1): 178.

36

Ghaffari H, Navaser M, Refahi S. In regard to Cuccia et al.: impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiat Oncol. 2020; 15(1): 199.

37

Afkhami Ardekani M, Ghaffari H, Navaser M, Zoljalali Moghaddam SH, Refahi S. Effectiveness of rectal displacement devices in managing prostate motion: a systematic review. Strahlenther Onkol. 2021; 197(2): 97-115.

38

Poon DMC, Yang B, Geng H, et al. Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer [published online ahead of print, 2022 Feb 24]. J Cancer Res Clin Oncol. 2022; 1-10.

39

Tanyi JA, He T, Summers PA, et al. Assessment of planning target volume margins for intensity-modulated radiotherapy of the prostate gland: role of daily inter- and intrafraction motion. Int J Radiat Oncol Biol Phys. 2010; 78(5): 1579-1585.

Precision Radiation Oncology
Pages 127-135
Cite this article:
Yang B, Yuan J, Poon DM, et al. Assessment of planning target volume margins in 1.5 T magnetic resonance-guided stereotactic body radiation therapy for localized prostate cancer. Precision Radiation Oncology, 2022, 6(2): 127-135. https://doi.org/10.1002/pro6.1155

372

Views

2

Crossref

1

Scopus

Altmetrics

Received: 24 March 2022
Revised: 22 April 2022
Accepted: 22 April 2022
Published: 12 May 2022
© 2022 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Return